Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming investor conferences:
Shareholders in Synlogic, Inc. (NASDAQ:SYBX) had a terrible week, as shares crashed 24% to US$1.59 in the week since...
Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 9.80% year over year to ($0.46), which missed the estimate of ($0.43).Revenue of $100,000 less by 70.41% year over year, which missed the estimate of $450,000.Guidance Earnings guidance hasn't been issued by the company for now.Synlogic hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 08, 2020View more earnings on SYBXWebcast URL: https://edge.media-server.com/mmc/p/o38dmqqmRecent Stock Performance 52-week high: $10.01Company's 52-week low was at $1.35Price action over last quarter: Up 44.65%Company Profile Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.See more from Benzinga * Recap: Red Lion Hotels Q1 Earnings * Recap: Ocwen Financial Q1 Earnings * Recap: Fly Leasing Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2019.
Synlogic (Nasdaq: SYBX) announced today that Richard Riese, M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16th, 2020.
As of late, it has definitely been a great time to be an investor in Synlogic.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic™ medicines, today provided an update on its business operations and expected clinical activities as a result of the COVID-19 pandemic. In the interest of patient safety, as well as aligning with the needs of clinical sites, Synlogic expects that enrollment of subjects into its planned Phase 2 clinical study of SYNB1618 in patients with phenylketonuria (PKU) will be delayed and expects slower enrollment of new subjects into its ongoing Phase 1 clinical trial of SYNB1891.
Synlogic (Nasdaq: SYBX) today will host its first Virtual R&D; Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic's Synthetic Biotic platform and programs for the treatment of metabolic diseases, inflammatory and immune disorders, and cancer. In addition, guest speaker David S. Goldfarb, M.D., Professor of Medicine and Physiology, NYU School of Medicine, Clinical Chief, Nephrology Division, NYU Langone Health, Chief, Nephrology Section, New York VA Medical Center, will present an overview of enteric hyperoxaluria and a patient perspective.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical company, for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the first quarter ended March 31, 2020.
Q1 2020 Synlogic Inc Earnings Call
As of late, it has definitely been a great time to be an investor Synlogic
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2019 financial results after the market closes on Thursday, March 12, 2020. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.
Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D; Event at 12:30 pm ET on Wednesday, May 27th, 2020.
While not a mind-blowing move, it is good to see that the Synlogic, Inc. (NASDAQ:SYBX) share price has gained 21% in...
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2020 financial results before the market opens on Friday, May 8, 2020. The press release will be followed by a conference call at 8:00 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Synlogic, Inc. (NASDAQ:SYBX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eastern ...
Q4 2019 Synlogic Inc Earnings Call